The Seattle-based biotech company Tasso has received FDA clearance for its simple sample collection device, the Tasso+ lancet.
The at-home self-collection device allows users to place the device on their upper arm to fill a small tube of blood from the capillaries through a virtually painless push-button suction method. The company plans to take the collection device nationwide to pharma companies, health care organizations and academic centers by the end of 2022.
“With continued industry interest in decentralized clinical trials and diverse testing applications, demand for our high-quality, virtually painless, convenient blood collection solutions is at an all-time high,” said CEO Ben Casavant. “This FDA Class II medical device clearance will help improve patient care by relieving traditional phlebotomy-related bottlenecks and enabling more individuals to get the tests they need at the time they are needed.”